Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, Áñez G, Shi J, Pan J, Hagenbach A, Von Barbier D, Varghese K, Jordanov E, Dhingra MS. Zambrano B, et al. Pediatr Res. 2024 Mar;95(4):1159. doi: 10.1038/s41390-023-02835-4. Pediatr Res. 2024. PMID: 37853068 Free PMC article. No abstract available.
A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B. López P, et al. Among authors: b chir s, zambrano b. Pediatr Infect Dis J. 2017 Nov;36(11):e272-e282. doi: 10.1097/INF.0000000000001682. Pediatr Infect Dis J. 2017. PMID: 28719500 Clinical Trial.
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
Matsuoka O, Ujiie M, Kikuchi H, Otake S, Chansinghakul D, Inoue T, Varghese K, Sirisuphmitr N, Hashiguchi T, Zambrano B, Nakama T, Frago C, Jordanov E, Dhingra MS. Matsuoka O, et al. Among authors: zambrano b. Jpn J Infect Dis. 2023 May 24;76(3):174-182. doi: 10.7883/yoken.JJID.2022.272. Epub 2023 Jan 31. Jpn J Infect Dis. 2023. PMID: 36724939 Free article. Clinical Trial.
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, Áñez G, Shi J, Pan J, Hagenbach A, Von Barbier D, Varghese K, Jordanov E, Dhingra MS. Zambrano B, et al. Pediatr Res. 2023 Sep;94(3):1035-1043. doi: 10.1038/s41390-023-02478-5. Epub 2023 Mar 10. Pediatr Res. 2023. PMID: 36899125 Free PMC article. Clinical Trial.
"Direct and indirect impacts of the COVID-19 pandemic on operational conduct of pediatric vaccine clinical trials".
McArthur MA, Bchir S, Dubois E, Gan L, Gerchman E, Gupta S, Liabis O, Perez L, Roche F, Vasquez G, Zambrano B, Gurunathan S, Dhingra MS. McArthur MA, et al. Among authors: zambrano b. Hum Vaccin Immunother. 2023 Dec 15;19(3):2272535. doi: 10.1080/21645515.2023.2272535. Epub 2023 Nov 9. Hum Vaccin Immunother. 2023. PMID: 37942563 Free PMC article.
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group. Hadinegoro SR, et al. Among authors: zambrano b. N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27. N Engl J Med. 2015. PMID: 26214039 Free article. Clinical Trial.
Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
Coronel D, García-Rivera EJ, Rivera DM, Arredondo-García JL, Dietze R, Perroud AP, Cortés M, Bonaparte M, Wang H, Pagnon A, Jantet-Blaudez F, Peñalosa LAR, Dayan G, Zambrano B, DiazGranados CA, Noriega F. Coronel D, et al. Among authors: zambrano b. Pediatr Infect Dis J. 2020 Oct;39(10):961-968. doi: 10.1097/INF.0000000000002830. Pediatr Infect Dis J. 2020. PMID: 32932330 Clinical Trial.
Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
Arredondo-García JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, Tran NH, Deseda CC, Wirawan DN, Cortés Supelano M, Frago C, Langevin E, Coronel D, Laot T, Perroud AP, Sanchez L, Bonaparte M, Limkittikul K, Chansinghakul D, Gailhardou S, Noriega F, Wartel TA, Bouckenooghe A, Zambrano B; CYD-TDV Dengue Vaccine Study Group. Arredondo-García JL, et al. Among authors: zambrano b. Clin Microbiol Infect. 2018 Jul;24(7):755-763. doi: 10.1016/j.cmi.2018.01.018. Epub 2018 Feb 8. Clin Microbiol Infect. 2018. PMID: 29408333 Free article.
74 results